Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RSV vaccine trial offers hope for transplant patients

NCT ID NCT07092865

Ongoing ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study looks at how well an RSV vaccine works and how safe it is in adults who have had a lung or kidney transplant. About 184 participants will receive the vaccine to see if their immune response lasts and if a booster dose is safe. The goal is to help protect transplant recipients from serious RSV infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

  • GSK Investigational Site

    Lexington, Kentucky, 40536, United States

  • GSK Investigational Site

    St Louis, Missouri, 63110, United States

  • GSK Investigational Site

    Omaha, Nebraska, 68198, United States

  • GSK Investigational Site

    New York, New York, 10065, United States

  • GSK Investigational Site

    Pittsburgh, Pennsylvania, 15213, United States

  • GSK Investigational Site

    Temple, Texas, 76502, United States

  • GSK Investigational Site

    Camperdown, New South Wales, 2050, Australia

  • GSK Investigational Site

    Birtinya, Queensland, 4556, Australia

  • GSK Investigational Site

    Herston, Queensland, 4029, Australia

  • GSK Investigational Site

    Edmonton, Alberta, T6G 2B7, Canada

  • GSK Investigational Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • GSK Investigational Site

    London, Ontario, N6A 5A5, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5G 2N2, Canada

  • GSK Investigational Site

    Giessen, 35392, Germany

  • GSK Investigational Site

    Milan, 20122, Italy

  • GSK Investigational Site

    Milan, 20132, Italy

  • GSK Investigational Site

    Palermo, 90127, Italy

  • GSK Investigational Site

    Pavia, 27100, Italy

  • GSK Investigational Site

    Siena, 53100, Italy

  • GSK Investigational Site

    Aichi, 466-8650, Japan

  • GSK Investigational Site

    Aichi, 470-1192, Japan

  • GSK Investigational Site

    Fukuoka, 814-0180, Japan

  • GSK Investigational Site

    Hyōgo, 663-8241, Japan

  • GSK Investigational Site

    Kumamoto, 861-8520, Japan

  • GSK Investigational Site

    Okayama, 700-8558, Japan

  • GSK Investigational Site

    Tokyo, 193-0998, Japan

  • GSK Investigational Site

    Seoul, 03722, South Korea

  • GSK Investigational Site

    Seoul, 110-774, South Korea

  • GSK Investigational Site

    A Coruña, 15006, Spain

  • GSK Investigational Site

    Barcelona, 8036, Spain

  • GSK Investigational Site

    Barcelona, 8907, Spain

  • GSK Investigational Site

    Córdoba, 14004, Spain

  • GSK Investigational Site

    Madrid, 28007, Spain

  • GSK Investigational Site

    Madrid, 28034, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Santander, 39011, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.